Treatment of early stage Supraglottic squamous cell carcinoma: Meta-analysis comparing primary surgery versus primary radiotherapy

Abstract

Objectives

For early stage supraglottic squamous cell carcinoma (SCC), single modality treatment either in the form of primary organ preservation surgery alone or radiation alone is recommended. Thus, a definite treatment strategy for early stage supraglottic SCC remains undefined. The primary objective of this study was to conduct a systematic review and meta-analysis comparing the oncologic outcomes of surgery and radiotherapy in early stage (Stage I and II) T1 N0 and T2 N0 supraglottic SCC.

Methods

Systematic methods were used to identify published and unpublished data. Two reviewers independently screened all titles, abstracts and articles for relevance using predefined criteria. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.

Results

Five studies met the inclusion criteria for disease specific mortality with a total of 2864 pooled patients. 5-year disease specific mortality was lower in the surgery group (ORs 0.43, 95% CI 0.31–0.60). Four studies met the inclusion criteria for 5-year overall mortality with a total of 2790 pooled patients. Five-year overall mortality was lower in surgery group (ORs 0.40, 95% CI 0.29–0.55).

Conclusions

This is the first study to examine the management of early stage supraglottic SCC using meta-analytic methodology. Our results suggest that primary surgery may result in decreased disease specific and overall mortality compared to primary radiotherapy.

Keywords

Early stage Supraglottic squamous cell carcinoma Supraglottic SCC Outcomes Meta-analysis

Background

Early stage supraglottic squamous cell carcinoma (SSCC) is defined as T1 (tumor limited to one subsite of supraglottis with normal vocal cord mobility) or T2 (tumor invading more than one adjacent subsite of supraglottis or glottis or region outside of supraglottis), with no regional nodal spread [1]. In a large review of nearly 160,000 cases of laryngeal SCC in the United States, the incidence of SSCC was noted to be 33% [2]. National Comprehensive Cancer Network (NCCN) guidelines for treatment of early stage SSCC suggest either organ preservation strategy – surgery with/without neck dissection or definitive radiation (RT) [3]. Early stage SSCC are small, however the 5-year survival of early stage SSCC is 64% [4, 5]. This is thought to be due to rich lymphatic supply of the area making it more likely to have occult regional and distant metastasis. Over the last 30 years, the oncologic outcomes for SSCC have not improved [2, 5, 6]. In fact, a review of National Cancer Database found that 5-year relative survival from SSCC decreased 52.2% (1985–1987) to 47.3% (1994–1996). The greatest decline in survival was in early stage SSCC patients with T1 N0 and T2 N0 disease.

Despite the poor survival of patients with early stage SSCC, there are a limited number of studies that have directly compared the survival outcomes of surgery versus radiation for early stage SSCC [7–16]. There are no prospective clinical trials, and the majority of the studies reported are small and retrospective. To date no meta-analysis comparing the survival outcomes for early stage SSCC comparing radiation and surgery has been reported. Our objectives were to, systematically review the literature to find all the relevant studies directly comparing surgery with radiation for early stage SSSC, synthesize the results and perform meta-analysis when possible of overall survival, disease specific survival and loco-regional control.

Methods

A systematic review protocol was developed a priori to ensure the objectives and aims were outlined from the outset. This was approved by PROSPERO in November 2015 (CRD42015026590).

Randomized controlled trials, head-to-head comparative studies, observational studies, case series (greater than 3 patients) were assessed. Studies comparing surgery (open organ preservation (OPS), transoral endoscopic laser microsurgery (TLM) or transoral robotic surgery(TORS)) with/without neck dissection to definitive radiotherapy (RT) were included. Single arm studies that reported results of open surgery, transoral surgery alone or radiotherapy alone were not considered., due to the inherent selection biases and lack of ability to compare results between different modalities of treatment. The study population was limited to patients aged 18 and older and diagnosed with early stage supraglottic SCC (Tis, T1 N0, T2 N0).

Included studies were assessed for the following oncologic outcomes: 5-year overall mortality (OM); 5-year disease-specific mortality (DSM); 5-year local control (LC); 5-year laryngectomy free survival (LFS); and functional outcomes (quality of life, swallowing and voice quality).

Computerized bibliographic databases: Medline, EMBASE and Cochrane Central Register of Controlled Trials were searched to identify studies. English language records were included from January 1990 to May 2015. Search strategy was designed by two authors (K.B.P and S.D.M.) and an experienced librarian.

Two authors (K.B.P and S.D.M.) reviewed the titles, abstracts and full texts of the studies independently, with disagreements resolved by consensus. Interobserver agreement was analyzed with quadratic-weighted kappa. Titles were screened for the keywords: “squamous cell carcinoma” and “supraglottic”, or “supraglottis”, or “glottic”, or “glottis”, or “larynx”, or “laryngeal”. All abstracts of the studies that met the eligibility criteria were then screened. The full text of studies that met the criteria were then included. Newcastle-Ottawa quality assessment scale for cohort studies was used determine the quality of the studies [17]. The relevant data on outcome measures were extracted with the use of standardized data extraction forms. Not all studies contained data on all of the outcome measures.

Statistical Analysis was performed by Review Manager 5.3. Dichotomous outcomes were compared using odds ratios (OR) or weighted mean differences and 95% confidence intervals (CI). Heterogeneity across the studies was evaluated by the chi-square statistic and significance was set at p < 0.1. The I2 test was used to measure the extent of inconsistency among results. Fixed effects model was used given the assumption that included studies are only representative samples of all potentially available studies. The Z statistic was used to test for overall pooled effect and significance was set at p < 0.05.

Results

The search strategy produced 5867 records. After removing 2026 duplicate records, the final number of unique records was 3841. After reviewing 3841 titles, 1098 studies were selected for reviewing the abstracts. Sixty-two abstracts were deemed appropriate for inclusion. After reviewing abstracts, 16 studies were deemed appropriate for inclusion and the full text was reviewed. Only 7 studies met the final inclusion criteria after reviewing the full text. Figure 1 illustrates the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart to identify the appropriate studies. Kappa statistic for the agreement at the abstract screening stage was 0.57 (CI 0.46–0.67).

Fig. 1

PRISMA Flowchart

Study characteristics and methodologic quality

No randomized controlled trials were found that compared the oncologic and functional outcomes of primary surgery versus RT. Of the seven studies included in the analysis, seven were retrospective and none were prospective in design. The total number of patients was 418 in the surgical arm, with patients undergoing organ preservation surgery with or without neck dissections. There were 2397 patients in the RT arm. Characteristics of the included studies are summarized in Table 1. Table 2 summarizes number of patients in each treatment group. Table 3 summarizes the quality of the included studies.

Table 1

Demographic characteristics of studies comparing survival outcomes between Surgery and Radiotherapy

Study	Median Age (years)		Gender (M/F)		Median Follow up (years)
	RT	OPS	RT	OPS	RT	OPS
Arshad 2014 [7]	63	58	1476/802	119/48	NR	NR
Jones 2004 [10]	63^a	61^a	NR	NR	8.5	9.6
Orus 2000 [12]	63.5^a	58.1^a	NR	NR	1.5
Santos 1998 [13]	56		NR	NR	NR
Sessions 2005 [14]	N/A	N/A	NR	NR	> 5
Spector 1995 [15]	61.3		41/12		NR	NR
Spriano 1997 [16]	62		141/16		5

^anumbers represent means Abbreviations: RT Radiotherapy, OPS Organ Preservation Surgery, NR Not Reported

Table 2

Staging characteristics of studies comparing survival outcomes between Surgery and Radiotherapy

Study	RT		OPS +/− ND
	T1	T2	T1	T2
Arshad 2014 [7]	1043	1235	92	75
Jones 2004^a [10]	90		41
Orus 2000^b [12]	27	63	11	14
Santos 1998^c [13]	3	6	3	6
Sessions 2005 [14]	5	5	90	102
Spector 1995^d [15]	4	1	1	2
Spriano 1997^a [16]	91		66

RT Radiotherapy, OPS Organ Preservation Surgery, ND Neck Dissection

^aT1 and T2 reported together, ^bAll OPS patients received ND, 7 patients received post-operative RT, ^cPatients received post-operative RT, ^dOnly Aryepiglottic fold

Table 3

Quality of the studies reporting survival outcomes between Surgery and Radiotherapy (Newcastle-Ottawa Scale)^†

Study	Selection				Comparability	Outcome			Score*
	Representativeness of exposed cohort	Selection of non exposed cohort	Ascertainment of exposure	Outcome not present at outset of study		Assessment	F/U Length	Adequacy of F/U
Arshad 2014 [7]	*	*	*	*	**	*	*	*	9
Jones 2004 [10]	*	*	*	*	**	*	*	*	9
Orus 2000 [12]	*	*	*	*		*	*	*	7
Santos 1998 [13]	*	*	*	*	*	*	*		7
Sessions 2005 [14]	*	*	*	*		*	*	*	7
Spector 1995 [15]	*	*	*	*	**	*	*	*	9
Spriano 1997 [16]	*	*	*	*	*	*	*	*	8

*Maximum total score that a study can get is 9

^†A study can receive a maximum of 1 asterisk for each numbered item within the selection and outcome categories. A maximum of 2 asterisks can be given for comparability

Oncologic outcomes

Of the seven studies included that were head-to-head studies, all seven contained data on oncologic outcome. Among them, data on overall survival were reported in four studies, data on disease specific survival were reported in five studies, data on local control were reported in one study.

Median age of the patients in the included studies was similar across the different studies. There were similar number of T1 and T2 patients within the RT and OPS groups for each study. There were higher number of patients in the RT group compared to the OPS +/− ND group.

5-year overall mortality (OM)

With respect to 5-year OM, in the head-to-head studies, there were 403 patients in the OPS with/without arm and 2387 patients in the RT arm in four studies. The results of pooled effect showed that the OR was 0.4 with 95% CI 0.29–0.55 favoring OPS with/without ND (Fig. 2).

Fig. 2

Forest Plot of comparison between organ preservation surgery and primary radiotherapy with respect to 5-year Overall Mortality

5-year disease-specific mortality (DSM)

With respect to 5-year DSM, in the head-to-head studies, there were 310 patients in the OPS with/without ND arm and 2554 patients in the RT arm in five studies. The results of pooled effect showed that the OR was 0.43 with 95% CI 0.31–0.59 favoring OPS with/without ND (Fig. 3).

Fig. 3

Forest Plot of comparison between organ preservation surgery and primary radiotherapy with respect to 5-year Disease-Specific Mortality

5-year local control (LC)

With respect to 5-year LC, in the head-to-head studies, there were 25 patients in the OPS arm and 90 patients in the RT arm in one study. The results of pooled effect showed that the OR was 0.71 with 95% CI 0.22–2.32 (Fig. 4).

Fig. 4

Forest Plot of comparison between organ preservation surgery and primary radiotherapy with respect to 5-year local recurrence

5-year larynx preservation

No head-to-head studies were identified that compared the laryngeal preservation after surgery and radiotherapy.

Functional outcomes

No head-to-head studies were identified that compared the functional outcomes after surgery and radiotherapy.

Discussion

To our knowledge, this is the first meta-analysis comparing the survival outcomes of surgery versus radiotherapy for early-stage SSCC. Pooled analysis for 5-year OM favors OPS with/without ND over RT with OR of 0.4 (95% CI 0.29–0.55). These results however do need to be interpreted with caution as the heterogeneity was high amongst the studies with a significant p-value for the heterogeneity. Pooled analysis for 5-year DSM favors OPS with/without ND over RT with OR of 0.43 (95% CI 0.31–0.59). In this case the heterogeneity was low amongst the studies with a non-significant p-value for the heterogeneity, thus suggesting that these results are valid. Additionally, a jack-knife analysis was done to determine the validity of the results and to ensure that excessive contribution by one of the studies was not skewing the conclusions. The results of the jack-knife analysis produced similar results which were statistically significant and favoring OPS with/without ND. Only one study examined rate of local control which also showed better outcomes with OPS. Unfortunately, functional comparisons could not be made due to paucity of studies in the literature.

Strengths

This review has several strengths. The review was designed, conducted and reported in accordance with published guidelines (PRISMA) and our protocol and search strategy was published a priori. To our knowledge, this is the first comprehensive review of all available literature comparing surgery versus radiation for patients with early stage SSCC. A comprehensive search strategy was undertaken and led to the review of 3841 unique citations of which seven studies met our inclusion criteria. This resulted in the analysis of 3086 patients with early stage SSCC.

Limitations

There were no head-to-head studies that compared TLM or TORS to RT in oncologic or functional outcomes for early stage supraglottic cancer. As with all meta-analyses, the strength of the conclusions that can be drawn from this study depend on the quality of the primary studies. Although, we only included studies published from 1990 and onwards, some of the studies in our review included patients treated well before that time period. Due to poor quality of CT scanners before 1990, some patients may have had regional nodal disease (thus advanced stage disease) which was not apparent on a poor quality scan. Additionally, many of the contemporary modalities of treatment such intensity modulated radiotherapy (IMRT), Chemo-radiotherapy, TLM and TORS were not in clinical practice prior to 1990. All seven studies that met the inclusion criteria were retrospective, there were no randomized controlled trials. Retrospective studies have their inherent biases including selection biases, wherein patients with other health comorbidities would have been poor surgical candidates and would have likely received radiotherapy. Significant heterogeneity was noted between the studies. Not all studies included the type of radiation and the radiotherapy protocol used to treat these SSCC, the recruitment period for the patients was different which may have resulted in different radiotherapy protocols being used for the patients. In the surgical group, not all patients may have received the same extent of surgery including elective neck dissections. With regards to weight of the individual studies, Arshad et al. had the majority of the patients that were included in our analysis and thus their study was weighted proportionally larger skewing the results [7]. We only considered English language studies for our meta-analysis; this did limit the number of titles screened and studies included however, the effect of this would likely be small. OR were used for our statistical analysis as time to event (Hazard Ratios) could not be used given the lack of consistency in reporting the outcomes in the included studies.

Surgery and radiotherapy for early stage SSCC

There are several advantages of RT. Although we did not find any head-to-head comparison studies assessing functional outcomes of RT in SSCC, it has been reported to have better functional outcomes in glottic cancers. Additionally, RT can be used in patients who are not candidates for OPS due to their underlying medical conditions. Risks of using RT in treating early stage SSCC is that this patient population does have a higher risk of developing a second primary malignancy in the aerodigestive tract [4, 5, 18]. If radiation is used as the primary treatment modality, most patients can only be salvaged with surgery and in the case of recurrent or new laryngeal cancer the treatment is almost always total laryngectomy.

Surgical approaches include open surgery or transoral surgical approaches, including laser (TLM) and robotic (TORS) and has several advantages over RT. As mentioned, patients with SSCC have a reasonable 5-year overall survival rates with a risk of developing second primary aerodigestive tract malignancy [4, 5, 18]. Surgery can thus be utilized as the first line and if there is failure, radiation can be used for salvage. Another advantage of surgery is the cost benefit of surgical intervention over radiotherapy. Cost analysis of open supraglottic laryngectomy, TLM and TORS by Dombree et al. in a Belgian model suggests that open supraglottic laryngectomy is almost equal to TLM in upfront surgical costs and TORS tends to be more expensive primarily due to purchase and maintenance costs [19]. This cost-analysis did not account for in-hospital costs such as length of admission, complications or readmission rates. Cost analysis comparing radiotherapy and TLM in a Canadian model for treatment of glottic cancers showed TLM to be a better cost saving modality [20].

One of the advantage of OPS with neck dissection is to identify patients with occult nodal metastasis in the neck. This is an important consideration given that up to 30% patients with SSCC may have occult nodal metastasis [21]. Thus, although these patients were early stage at the time of recruitment, the discovery of positive nodal metastasis after elective neck dissection results in the patients being upstaged and adjuvant radiotherapy is usually recommended. Some of the patients included in our study who underwent an elective neck dissection received adjuvant radiotherapy for positive nodal disease [12, 13]. This may in part be one of the reasons why patients in our study in the surgical arm had improved oncologic outcomes. Results from Arshad et al. corroborate this, as patients who underwent OPS with neck dissections fared better than those who only underwent RT or OPS without neck dissections [7].

Disadvantages of surgery include risk of general anesthetic, especially in patients with significant comorbidities, bleeding, infection, pharyngocutaneous fistula, dysphagia and tracheostomy. Additionally, one of the main criticisms of OPS are the associated poor functional outcomes [22]. However, TLM and TORS have gained popularity recently, due to several advantages of transoral surgery over open surgery and RT. TLM was first introduced by Strong and Jako for laryngeal surgery [23]. Since then several reports have been published investigating the role of TLM for supraglottic laryngectomy [23–36]. Long-term oncologic outcomes comparing TLM and open surgery suggest that oncologic outcomes are similar. Cabanillas et al. compared TLM versus open laryngeal preservation surgery in a total of fifty-two patients, who also underwent concurrent bilateral neck dissections, and found that 5-year DSS was 80% in the TLM group versus 72% in the open surgical group and 5-year local control rate was 70% in both groups [34]. Transoral laser surgery, when compared to open surgery, resulted in reduced incidence of permanent gastrostomies and tracheostomies [37]. Importantly, the survival outcomes were no different between the two groups.

TORS was first described by Weinstein and colleagues, and since then there have been several reports assessing its oncologic and functional outcomes, the majority of the studies report on all stages of supraglottic SCC [32, 38–49]. Although, long-term oncology outcomes have not been reported, initial results with mean follow up ranging from 6.8 to 28.1 months, indicate that locoregional control is the same as RT [38, 41, 44]. Additionally, long-term tracheostomy and gastric feeding tube rates range from 0 to 20% in patients treated with TORS [38, 41, 44].

Given the paucity of high level evidence guiding the optimal management of early stage supraglottic cancer and potential biases of retrospective studies, a head to head comparison between newer modalities such as TLM and/or TORS with RT is crucial in determining the therapeutic algorithm that can yield better oncologic and functional outcomes in early stage SSCC patient. Although studies comparing surgery and radiation have been challenging to accrue to, ongoing efforts comparing OPS to RT for oropharyngeal cancer are underway and actively accruing [50, 51]. This high level of evidence will ultimately be necessary to guide the guide treatment of these patients with early stage disease that have a surprisingly poor prognosis.

Conclusions

To our knowledge, this is the first meta-analysis comparing RT and OPS for early stage SSCC. Patients who underwent OPS had better survival outcomes compared to primary radiation therapy. Five studies met the inclusion criteria for disease specific mortality with a total of 2864 pooled patients. 5-year disease specific mortality was lower in the surgery group (ORs 0.43, 95% CI 0.31–0.60). Four studies met the inclusion criteria for 5-year overall mortality with 5-year overall mortality being lower in surgery group (ORs 0.40, 95% CI 0.29–0.55). We were unable to compare the functional outcomes. Given the paucity of studies in the literature comparing open surgery, TLM, TORS and radiotherapy evaluating both oncologic and functions outcomes, future studies and research should include well designed randomized controlled trials.

Footnotes

Acknowledgements

Authors’ information

KBP – PGY 5 Resident, Otolaryngology – Head and Neck Surgery, Western University, London, Ontario.

ACN – Associate Professor, Otolaryngology – Head and Neck Surgery, Western University, London, Ontario.

KF – Professor, Otolaryngology – Head and Neck Surgery, Western University, London, Ontario.

JY – Professor, Otolaryngology – Head and Neck Surgery, Western University, London, Ontario.

SDM – Assistant Professor, Otolaryngology – Head and Neck Surgery, Western University, London, Ontario.

Ethics approval and consent to participate

Not Applicable. This was a meta-analysis.

Consent for publication

Not applicable. No patients were directly involved and thus no consent for publication is required.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abbreviations

References

Edge

SBD

Compton

Fritz

Greene

Trotti

AAJCC

Cancer staging handbook 2010

New York

Springer-Verlag

Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006:116:1–13.

NCCN clinical practice guidelines in oncology in Head and Neck Cancers (version 1.2015). http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (2015). Accessed 10 Nov 2015.

Piccirillo F. Cancer of the larynx in SEER survival monograph: cancer survival among adults: U.S. SEER Program 1988–2001, Patient and Tumor Characteristics. National Cancer Insitutite, SEER Program. NIH Pub. No, 07–6215, Bethesda, MD, 2007.

Cosetti

Schantz

Five-year survival rates and time trends of laryngeal cancer in the US population

Arch Otolaryngol 2008 134 370 379 10.1001/archotol.134.4.370

Chen

Fedewa

Zhu

Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007

Arch Otolaryngol 2011 137 1017 1024 10.1001/archoto.2011.171

Arshad

Jayaprakash

Gupta

Survival differences between organ preservation surgery and definitive radiotherapy in early supraglottic squamous cell carcinoma

Otolaryngol Head Neck Surg 2014 150 237 244 10.1177/0194599813512783 24255085

Bron

Soldati

Zouhair

Treatment of early stage squamous-cell carcinoma of the glottic larynx: endoscopic surgery or cricohyoidoepiglottopexy versus radiotherapy

Head Neck 2001 23 823 829 1:STN:280:DC%2BD3Mrkt1Oquw%3D%3D 10.1002/hed.1120 11592228

Chun

Kim

Choi

Byeon

Jung

Kim

The oncologic safety and functional preservation of supraglottic partial laryngectomy

Am J Otolaryngol 2010 31 246 251 10.1016/j.amjoto.2009.02.007 20015754

10.

Jones

Fish

Fenton

Husband

The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation?

Head Neck. 2004 26 127 135 10.1002/hed.10361 14762881

11.

Laccourreye

Weinstein

Chabardes

Housset

Laccourreye

Brasnu

T1 squamous cell carcinoma of the arytenoid

Laryngoscope 1992 102 896 900 1:STN:280:DyaK38zls1OntQ%3D%3D 10.1288/00005537-199208000-00009 1495355

12.

Orus

Leon

Vega

Quer

Initial treatment of the early stages (I, II) of supraglottic squamous cell carcinoma: partial laryngectomy versus radiotherapy

Eur Arch Otorhinolaryngol 2000 257 512 516 1:STN:280:DC%2BD3M7jslaktQ%3D%3D 10.1007/s004050000276 11131380

13.

Santos

Kowalski

Magrin

Prognostic factors in supraglottic carcinoma patients treated by surgery or radiotherapy

Ann Otol Rhinol Laryngol. 1998 107 697 702 1:STN:280:DyaK1czot1Kjsw%3D%3D 10.1177/000348949810700812 9716873

14.

Sessions

Lenox

Spector

Supraglottic laryngeal cancer: analysis of treatment results

Laryngoscope 2005 115 1402 1410 10.1097/01.MLG.0000166896.67924.B7 16094113

15.

Spector

Sessions

Emami

Simpson

Haughey

Fredrickson

Squamous cell carcinomas of the aryepiglottic fold: therapeutic results and long-term follow-up

Laryngoscope 1995 105 734 746 1:STN:280:DyaK2Mzis1yrtA%3D%3D 10.1288/00005537-199507000-00012 7603279

16.

Spriano

Antognoni

Piantanida

Conservative management of T1-T2N0 supraglottic cancer: a retrospective study

Am J Otolaryngol 1997 18 299 305 1:STN:280:DyaK2svislWhtw%3D%3D 10.1016/S0196-0709(97)90023-5 9282245

17.

Newcastle-Ottawa Scale [type]. Updated http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 10 Nov 2015.

18.

Vaamonde

Martin

del Rio

LaBella

Second primary malignancies in patients with cancer of the head and neck

Otolaryngol Head Neck Surg. 2003 129 65 70 10.1016/S0194-5998(03)00476-5 12869919

19.

Dombree

Crott

Lawson

Janne

Castiaux

Krug

Cost comparison of open approach, transoral laser microsurgery and transoral robotic surgery for partial and total laryngectomies

Eur Arch Otorhinolaryngol 2014 271 2825 2834 10.1007/s00405-014-3056-9 24906840

20.

Phillips

Sader

Brown

Transoral laser microsurgery versus radiation therapy for early glottic cancer in Canada: cost analysis

J Otolaryngol Head Neck Surg 2009 38 619 623 19958723

21.

Byers

Wolf

Rationale

BAJ

For elective modified neck dissection

Head Neck Surg 1988 10 160 167 1:STN:280:DyaL1M7ntl2guw%3D%3D 10.1002/hed.2890100304 3235344

22.

Lewin

Hutcheson

Barringer

Functional analysis of swallowing outcomes after supracricoid partial laryngectomy

Head Neck 2008 30 559 566 10.1002/hed.20738 18098304 4012760

23.

Strong

Jako

Laser surgery in the larynx. Early clinical experience with continuous CO 2 laser

Ann Otol Rhinol Laryngol. 1972 81 791 798 1:STN:280:DyaE3s%2FkvVWmug%3D%3D 10.1177/000348947208100606 4636137

24.

Breda

Catarino

Monteiro

Transoral laser microsurgery for laryngeal carcinoma: survival analysis in a hospital-based population

Head Neck. 2015 37 1181 1186 10.1002/hed.23728 24798054

25.

Bussu

Almadori

De Corso

Endoscopic horizontal partial laryngectomy by CO(2) laser in the management of supraglottic squamous cell carcinoma

Head Neck. 2009 31 1196 1206 10.1002/hed.21085 19360749

26.

Canis

Martin

Ihler

Results of transoral laser microsurgery for supraglottic carcinoma in 277 patients

Eur Arch Otorhinolaryngol 2013 270 2315 2326 10.1007/s00405-012-2327-6 23306348 3699705

27.

Csanady

Czigner

Vass

Jori

Transoral CO2 laser management for selected supraglottic tumors and neck dissection

Eur Arch Otorhinolaryngol 2011 268 1181 1186 10.1007/s00405-011-1603-1 21516504

28.

Davis

Kriskovich

Galloway

3rd Buntin

Jepsen

Endoscopic supraglottic laryngectomy with postoperative irradiation

Ann Otol Rhinol Laryngol. 2004 113 132 138 10.1177/000348940411300210 14994769

29.

Grant

Salassa JR Hinni

Pearson

Hayden

Perry

Transoral laser microsurgery for carcinoma of the supraglottic larynx

Otolaryngol Head Neck Surg. 2007 136 6 900 10.1016/j.otohns.2006.12.015 17547977

30.

Iro

Waldfahrer

Altendorf-Hofmann

Weidenbecher

Sauer

Steiner

Transoral laser surgery of supraglottic cancer: follow-up of 141 patients

Arch Otolaryngol Head Neck Surg 1998 124 1245 1250 1:STN:280:DyaK1M%2FjslKqsg%3D%3D 10.1001/archotol.124.11.1245 9821928

31.

Peretti

Piazza

Ansarin

Transoral CO2 laser microsurgery for tis-T3 supraglottic squamous cell carcinomas

Eur Arch Otorhinolaryngol 2010 267 1735 1742 10.1007/s00405-010-1284-1 20499077

32.

Solares

Strome

Transoral robot-assisted CO2 laser supraglottic laryngectomy: experimental and clinical data

Laryngoscope 2007 117 817 820 10.1097/MLG.0b013e31803330b7 17473675

33.

Vilaseca

Blanch

Berenguer

Transoral laser microsurgery for locally advanced (T3-T4a) supraglottic squamous cell carcinoma: sixteen years of experience

Head Neck. 2016 38 7 1050 10.1002/hed.24408 26872432

34.

Cabanillas

Rodrigo

Llorente

Suarez

Oncologic outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach

Head Neck. 2008 30 750 755 10.1002/hed.20778 18228525

35.

Cabanillas

Rodrigo

Llorente

Suarez

Ortega

Suarez

Functional outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach

Head Neck. 2004 26 653 659 10.1002/hed.20063 15287032

36.

Kollisch

Werner

Lippert

Functional

Results following partial supraglottic resection. Comparison of conventional surgery vs. transoral laser microsurgery

Adv Otorhinolaryngol 1995 49 237 240 1:STN:280:DyaK2MzotF2jsg%3D%3D 7653374

37.

Karatzanis

Psychogios

Zenk

Evaluation of available surgical management options for early supraglottic cancer

Head Neck. 2010 32 1048 1055 10.1002/hed.21289 19953613

38.

Razafindranaly

Lallemant

Aubry

Clinical outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: experience of a French evaluation cooperative subgroup of GETTEC

Head Neck 2016 38 E1097 E1101 10.1002/hed.24163 26435046

39.

Weinstein

O'Malley

Jr Snyder

Hockstein

Transoral robotic surgery: supraglottic partial laryngectomy

Ann Otol Rhinol Laryngol 2007 116 19 23 10.1177/000348940711600104 17305273

40.

Durmus

Gokozan

Ozer

Transoral robotic supraglottic laryngectomy: surgical considerations

Head Neck. 2015 37 125 126 10.1002/hed.23645 24616067

41.

Ozer

Alvarez

Kakarala

Durmus

Teknos

Carrau

Clinical outcomes of transoral robotic supraglottic laryngectomy

Head Neck. 2013 35 1158 1161 10.1002/hed.23101 22907898

42.

Park

Byeon

Chung

Choi

Kim

Comparison of treatment outcomes after transoral robotic surgery and supraglottic partial laryngectomy: our experience with seventeen and seventeen patients respectively

Clin Otolaryngol 2013 38 270 274 1:STN:280:DC%2BC3svhsVKitQ%3D%3D 10.1111/coa.12101 23441587

43.

Park

Lee

Transoral robotic surgery (TORS) in laryngeal and hypopharyngeal cancer

J Laparoendosc Adv S 2009 19 361 368 10.1089/lap.2008.0320

44.

Dowthwaite

Nichols

Yoo

Transoral robotic total laryngectomy: report of 3 cases

Head Neck. 2013 35 E338 E342 10.1002/hed.23226 23471833

45.

Mendelsohn

Remacle

Transoral robotic surgery for laryngeal cancer

Curr Opin Otolaryngol Head Neck Surg 2015 23 148 152 10.1097/MOO.0000000000000144 25692623

46.

Mendelsohn

Remacle

Van Der Vorst

Bachy

Lawson

Outcomes following transoral robotic surgery: supraglottic laryngectomy

Laryngoscope 2013 123 208 214 10.1002/lary.23621 23008093

47.

Olsen

Moore

Koch

Price

Kasperbauer

Olsen

Transoral robotic surgery for supraglottic squamous cell carcinoma

Am J Otolaryngol 2012 33 379 384 10.1016/j.amjoto.2011.10.007 22133967

48.

Rodrigo

Suarez

Silver

Transoral laser surgery for supraglottic cancer

Head Neck 2008 30 658 666 10.1002/hed.20811 18327778

49.

Tsue

Girod

Functional swallowing outcomes following transoral robotic surgery vs primary chemoradiotherapy in patients with advanced-stage oropharynx and supraglottis cancers

JAMA Otolaryngol Head Neck Surg 2013 139 43 48 10.1001/jamaoto.2013.1074 23247974

50.

Nichols

Yoo

Hammond

Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)--study protocol for a randomized phase II trial

BMC Cancer 2013 13 133 10.1186/1471-2407-13-133 23514246 3621077

51.

EORTC 1420-HNCG-ROG “The best of” trial. http://www.eortc.org/research-groups/head-and-neck-cancer-group/ongoing-projects/. Accessed 10 Nov 2015.